123.94
5.24 (4.41%)
| Previous Close | 118.70 |
| Open | 122.10 |
| Volume | 980,125 |
| Avg. Volume (3M) | 994,837 |
| Market Cap | 7,118,461,952 |
| Price / Earnings (Forward) | 2.50 |
| Price / Sales | 13.57 |
| Price / Book | 10.66 |
| 52 Weeks Range | |
| Earnings Date | 17 Feb 2026 |
| Profit Margin | -30.57% |
| Operating Margin (TTM) | -19.39% |
| Diluted EPS (TTM) | -2.27 |
| Quarterly Revenue Growth (YOY) | 24.60% |
| Total Debt/Equity (MRQ) | 14.09% |
| Current Ratio (MRQ) | 6.49 |
| Operating Cash Flow (TTM) | -45.97 M |
| Levered Free Cash Flow (TTM) | -17.66 M |
| Return on Assets (TTM) | -6.68% |
| Return on Equity (TTM) | -20.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Glaukos Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.40 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 101.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Brown Capital Management Llc | 30 Sep 2025 | 762,760 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 160.00 (Stifel, 29.10%) | Buy |
| Median | 140.00 (12.96%) | |
| Low | 125.00 (Citigroup, 0.86%) | Buy |
| Average | 139.13 (12.26%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 117.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 18 Feb 2026 | 131.00 (5.70%) | Buy | 121.00 |
| 28 Jan 2026 | 131.00 (5.70%) | Buy | 123.94 | |
| Needham | 18 Feb 2026 | 127.00 (2.47%) | Buy | 121.00 |
| 14 Jan 2026 | 125.00 (0.86%) | Buy | 104.43 | |
| Wells Fargo | 18 Feb 2026 | 135.00 (8.92%) | Buy | 121.00 |
| Stifel | 22 Jan 2026 | 160.00 (29.09%) | Buy | 125.90 |
| Stephens & Co. | 02 Jan 2026 | 145.00 (16.99%) | Buy | 110.72 |
| UBS | 23 Dec 2025 | 145.00 (16.99%) | Buy | 116.18 |
| Truist Securities | 18 Dec 2025 | 145.00 (16.99%) | Buy | 113.21 |
| Citigroup | 11 Dec 2025 | 125.00 (0.86%) | Buy | 109.23 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | - | 119.17 | -4,059 | -483,711 |
| GILLIAM JOSEPH E | - | 119.17 | -1,057 | -125,963 |
| NAVRATIL TOMAS | - | 119.17 | -396 | -47,191 |
| Aggregate Net Quantity | -5,512 | |||
| Aggregate Net Value ($) | -656,865 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 119.17 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GILLIAM JOSEPH E | Officer | 24 Feb 2026 | Disposed (-) | 1,057 | 119.17 | 125,963 |
| NAVRATIL TOMAS | Officer | 24 Feb 2026 | Disposed (-) | 396 | 119.17 | 47,191 |
| BURNS THOMAS WILLIAM | Officer | 24 Feb 2026 | Disposed (-) | 4,059 | 119.17 | 483,711 |
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR |
| 20 Jan 2026 | Announcement | Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 |
| 13 Jan 2026 | Announcement | Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance |
| 16 Dec 2025 | Announcement | Glaukos Announces Participation in J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |